ADAG

Adagene Inc. (ADAG) - Form 20-F Summary for Fiscal Year Ended December 31, 2024

Business Context and Reporting Period

Company: Adagene Inc.
Reporting Period: Fiscal Year Ended December 31, 2024
Business Model: Clinical-stage biotechnology company focused on discovering and developing novel antibody-based cancer immunotherapies. The company utilizes its proprietary Dynamic Precision Library (DPL) platform to generate NEObodies, SAFEbodies, and POWERbodies.
Key Asset: Lead product candidate ADG126 (muzastotug), a masked anti-CTLA-4 SAFEbody currently in Phase 1b/2 clinical development for metastatic microsatellite-stable (MSS) colorectal cancer (CRC).
Corporate Structure: Cayman Islands holding company with substantive operations in China (Adagene Suzhou) and the United States (Adagene Incorporated).

Key Financial Metrics (Year Ended Dec 31, 2024)

Note: Revenue in 2024 was minimal ($0.1M) compared to 2023 ($18.1M), primarily due to the recognition of milestone payments from the Exelixis collaboration in the prior year. No product sales revenue has been generated to date.

Material Changes vs. Prior Period

• Revenue Decline: Licensing and collaboration revenue dropped significantly from $18.1 million in 2023 to $0.1 million in 2024. The 2023 figure included a $3.0 million milestone payment from Exelixis and revenue recognition from the Sanofi collaboration. No significant milestones were achieved in 2024.
• Net Loss Increase: Net loss increased by 76.4% to $33.4 million in 2024 from $18.9 million in 2023. This increase was driven by the sharp decline in revenue, partially offset by reductions in operating expenses.
• Expense Reductions:
  • R&D Expenses: Decreased by 21.4% to $28.8 million, reflecting a strategic prioritization of the ADG126 program and cost-control measures.
  • Administrative Expenses: Decreased by 16.1% to $7.3 million due to personnel reductions and lower office-related expenses.
• Liquidity: Cash and cash equivalents decreased by approximately $24.7 million to $85.2 million. The company utilized an At-The-Market (ATM) offering program in 2024, raising net proceeds of approximately $7.0 million.
• Debt Profile: Total borrowings decreased to $18.2 million from $21.9 million in 2023, with a significant portion ($12.9 million) classified as current liabilities due to upcoming maturities.

Guidance, Outlook, and Management Commentary

• Clinical Progress (ADG126): Management highlighted robust safety and efficacy data for ADG126 in combination with pembrolizumab for MSS CRC. At the 2025 ASCO GI Symposium, a 20 mg/kg loading dose regimen demonstrated a 33% Overall Response Rate (ORR). A Phase 2 neoadjuvant trial for Stage II/III colorectal cancer is expected to begin enrollment in April 2025.
• Pipeline Updates:
  • ADG206: A masked anti-CD137 POWERbody is in Phase 1 development.
  • Preclinical: Several IND-ready candidates (ADG138, ADG153) and discovery programs are advancing.
• Liquidity Outlook: Management believes current cash resources ($85.2 million) are sufficient to fund operations into the end of 2026. However, the company expects to continue incurring significant operating losses and will require additional financing to complete clinical development and commercialization.
• Collaborations: Active collaborations include Sanofi (SAFEbody technology), Exelixis (SAFEbody technology), and Merck (clinical supply of pembrolizumab). No new major collaboration revenue was recognized in 2024.

Risks and Contingencies

• Regulatory Risks (PRC/US): As a Cayman Islands company with operations in China, Adagene faces risks related to the Holding Foreign Companies Accountable Act (HFCAA). While the PCAOB currently has access to inspect auditors in China, future restrictions could lead to delisting from U.S. exchanges. Additionally, evolving PRC regulations on data security, human genetic resources, and overseas listings pose operational risks.
• Development Risks: The company has no approved products. Clinical trials may fail to demonstrate safety or efficacy, or regulatory approvals may be delayed or denied. ADG126 is still in Phase 1b/2.
• Financial Risks: The company has a history of net losses and an accumulated deficit of $311.2 million. Continued losses and the need for additional capital may lead to dilution of shareholders or restrictions on operations if financing is unavailable.
• PFIC Status: The company believes it was likely a Passive Foreign Investment Company (PFIC) for 2024 and may be one for 2025, which could result in adverse U.S. federal income tax consequences for U.S. investors.
• Related Party Transactions: Significant reliance on WuXi Biologics (a related party) for manufacturing and CRO services. Amounts due to WuXi Biologics were $12.6 million as of December 31, 2024.

Key Facts for Investor Verification

• Cash Runway: Verify the sufficiency of the $85.2 million cash balance to fund operations through the end of 2026, considering the high burn rate of clinical-stage biotech.
• Revenue Sustainability: Assess the likelihood of future milestone payments from Sanofi and Exelixis given the lack of revenue in 2024.
• Debt Maturities: Review the $12.9 million in current borrowings and the company's ability to refinance or repay these obligations without dilutive equity raises.
• HFCAA Compliance: Monitor the PCAOB's annual determination regarding its ability to inspect auditors in China to assess delisting risk.
• Clinical Data: Scrutinize the Phase 2 data for ADG126 in MSS CRC, specifically the durability of responses and safety profile at higher doses, as this is the primary value driver.
• Related Party Dependence: Evaluate the concentration risk associated with WuXi Biologics for manufacturing and the potential impact of any disruption in this supply chain.